MedTrace Logo

Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care

NCT04299022 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2025-04-02

No results posted yet for this study

Summary

Prospective registry and retrospective data collection study to assess the efficacy and safety of Vivigen Cellular Bone Matrix (Vivigen) in orthopaedic trauma patients who require bone grafting in the acute, delayed, non-union fracture as well as use in fusion procedure settings.

Conditions

  • Fractures, Bone
  • Nonunion of Fracture
  • Fractures, Open
  • Fractures, Ununited
  • Fracture, Tibial
  • Fracture of Femur
  • Fracture Arm

Interventions

OTHER

Vivigen Cellular Bone Matrix

Allograft bone matrix

Sponsors & Collaborators

  • LifeNet Health

    lead INDUSTRY

Principal Investigators

  • Alyce Jones, Ph.D · LifeNet Health

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2026-07-31
Completion
2026-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04299022 on ClinicalTrials.gov